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Summary
Rapid developments in genetic analysis have enabled the dissection of a variety of arthropathies that are inherited in a Mendelian manner.
These disorders include calcium crystal arthropathies such as calcium pyrophosphate dihydrate deposition (CPPD) disease and
hydroxyapatite deposition disease. In CPPD disease, mutations in a recently discovered gene, ANKH, have been demonstrated in ﬁve
affected families and may also be associated with the idiopathic deposition of calcium pyrophosphate dihydrate crystals. The product of ANKH
appears to be involved in cellular transport of inorganic pyrophosphate (PPi) and mutations in ANKH have been shown to have a signiﬁcant
impact on the regulation of intra- and extracellular levels of PPi. In families with hydroxyapatite deposition disease, no gene locus has yet been
linked to the disorder.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The familial forms of the calcium crystal-induced arthropa-
thies, speciﬁcally calcium pyrophosphate dihydrate (CPPD)
deposition disease and the basic calcium phosphate
disorders, occur in almost all ethnic groups and are
frequently characterized by early onset and severe clinical
manifestations. Although these inherited disorders are
relatively rare, they can often provide a means of identifying
critical constituents of biochemical pathways that are
important to the development of the familial as well as
idiopathic varieties of these disorders. Here we will review
the current status of gene discovery in chondrocalcinosis
and describe the putative role of these genes in the
development of these diseases.
Phenotype and genetic analyses
The history of the non-urate, calcium crystal arthropathies
dates to 1958 when Zitnan and Sitaj presented case studies
of 27 patients, most of whom were members of ﬁve families,
with what they referred to as articular chondrocalcinosis1,2.
The nature of the crystal deposition in affected patients was
clariﬁed by McCarty and Hollander3 who studied two cases
of non-urate associated crystal deposition in the joints of
patients thought to have gout. Radiographic examination of
the joints in these and other patients revealed distinctive
and abnormal calciﬁcations in and around articular hyaline
cartilage and ﬁbrocartilage. Following the initial description
of chondrocalcinosis in the ﬁve Czech families, multiple
ethnic series of affected families were reported4e20. Most
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Received 8 April 2005; revision accepted 17 April 2005.7familial cases appeared to be inherited in an autosomal
dominant manner with precocious onset and variable
clinical expression, with articular cartilage deposition of
calcium-containing crystals occurring before the develop-
ment of frank degenerative joint disease (see Fig. 1).
The radiographic features included crystal deposition in the
knee, symphysis pubis, and triangular ﬁbrocartilage of the
wrist6,21,22. A peculiar type of osteoarthritis with numerous
and large subchondral cysts was also observed.
The primary crystal types that are observed in chondro-
calcinosis include CPPD and basic calcium phosphate
including hydroxyapatite. With few exceptions (see below)
family studies of chondrocalcinosis demonstrate the pres-
ence of CPPD crystals in synovial aspirates. The mecha-
nisms responsible for the deposition of the CPPD crystals
are not known, although some studies have reported that
structural changes in articular cartilage extracellular matrix
might promote such a process23,24, thus prompting an
exploration of genes encoding cartilage extracellular matrix
proteins as candidate genes for chondrocalcinosis.
In a large family from the Chiloe Islands with a clinical
phenotype of severe osteoarthritis, late-onset spondyloepi-
physeal dysplasia, and chondrocalcinosis in multiple joints
and ﬁbrocartilages, a heterozygous mutation in the COL2A1
gene that resulted in an Arg to Cys substitution at amino
acid 75 in the type II collagen molecule was identiﬁed25,26.
However, it is likely that the chondrocalcinosis phenotype in
this kindred was a secondary consequence of the advanced
and severe osteoarthritis.
In addition to extracellular matrix proteins as potential
candidates for familial CPPD disease, numerous studies of
a chondrocyte nucleoside triphosphate pyrophosphohydro-
lase (NTPPPH) have suggested that the biochemical
pathway responsible for the generation of inorganic
pyrophosphate (PPi) may play a role in the crystal
deposition27e29. Increased levels of intracellular PPi have
been observed in cultured ﬁbroblasts and lymphoblasts of
patients affected with familial CPPD disease30,31, and in
synovial ﬂuids from an affected British family19, thus45
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metabolism may give rise to abnormal crystal deposition in
these families.
GENETIC LINKAGE ANALYSES IN FAMILIES
WITH CPPD DISEASE
The availability of numerous families presenting with
CPPD disease as a Mendelian trait has permitted the use of
parametric methods of linkage analysis to deﬁne potential
disease loci. A study of a large family from Maine, in which
the CPPD disease phenotype was associated with severe,
non-dysplastic osteoarthritis, excluded linkage to the COL2A1
locus; in this family, genetic linkage was demonstrated
between the disease phenotype and a locus on the long
arm of chromosome 8, now referred to as the CCAL1
locus32. The locus on chromosome 8q, although statistically
signiﬁcant, was broad and spanned a genetic interval of
approximately 30 cM, or a physical distance of over 25 Mbp.
Without additional family members from the original kindred,
or the availability of other families whose CPPD disease
phenotypes are linked to the CCAL1 locus, further
exploration of the genetic basis for linkage of CPPD
disease to chromosome 8q is limited.
Linkage analysis on a British CPPD disease family
subsequently identiﬁed a second chondrocalcinosis locus
on the short arm of chromosome 533 and was conﬁrmed in
genetic studies of two other families from France and
Argentina34. All of the families presented with typical
symptoms of CPPD disease and the large kindred from
Fig. 1. Radiograph of patient with familial CPPD disease. The knee
of a 42-year-old patient, a member of an Argentinean CPPD
disease kindred34 is shown. Note that there is minimal compro-
mise of joint space and structure of the tibial plateau and femoral
condyle at the early stage of disease in this individual; however,
prominent calciﬁcation of the articular cartilage is clearly visible
(indicated by arrow).the Alsace region of France described by Andrew et al., like
the British family reported by Hughes et al.33, had also been
extensively characterized with respect to abnormalities in
PPi metabolism30e31. The chromosome 5p15 locus, re-
ferred to as CCAL2, has now been shown to be linked to the
CPPD disease phenotype in ﬁve apparently unrelated
families, conﬁrming the fact that CCAL2 is an important
locus for familial chondrocalcinosis.
THE STATUS OF CANDIDATE GENES
FOR FAMILIAL CPPD DISEASE
The chromosome 5p15 locus contained a number of
positional genes that could serve as viable candidates for
familial CPPD disease. However, in a timely intersection of
research efforts, a gene for an animal model of aberrant
calciﬁcation was identiﬁed on mouse chromosome 15 in
a region of the chromosome that was syntenic to human
chromosome 5p35. The animal model was the progressive
ankylosis (ank) mouse, a naturally occurring autosomal
recessive mutant whose phenotype included the deposition
of hydroxyapatite in articular tissues and synovial ﬂuid. In
affected animals, disease progression includes joint space
narrowing, cartilage erosion and formation of osteophytes
that cause joint immobility and eventual fusion. Complete
rigidity and death occurs at around 6 months of age36e40.
Although the phenotype of the mouse model was
considerably different from that seen in human chondro-
calcinosis, the abnormal articular calciﬁcation and the fact
that the human homologue of the gene, referred to as
ANKH, was located at the CCAL2 locus, made it a viable
positional candidate gene. Furthermore, Ho et al. presented
evidence that the gene product of ank functioned to
regulate PPi levels in cells (see below). Mutational analyses
of ANKH detected four mutations in the ﬁve families in
which linkage to the CCAL2 locus had been conﬁrmed. In
the family described by Hughes et al., a heterozygous base
substitution at position 11 of the 5# untranslated region
(UTR) introduced a new methionine (ATG) codon. Pend-
leton et al.41 performed in vitro translation studies and mass
determination of the resultant protein by electrospray
ionization mass spectrometry to demonstrate that the
upstream ATG sequence was recognized as a new trans-
lational start site. In the Argentinean and French families,
heterozygous missense mutations were observed in highly
conserved amino acids in the ﬁrst and second exons,
respectively41,42. Two US CPPD disease families have
mutations at the same amino acid position as that observed
in the Argentinean kindred; however, the sequence variants
in the two US families are transversion mutations, while
that in the Argentinean family is a transition mutation42,43.
Haplotype analyses of microsatellite and single nucleotide
polymorphic markers in all three families demonstrate that
they are not related, suggesting that the mutations at the
same amino acid arose independently of each other, and
that this site may represent a ‘‘hot spot’’ for mutations in
CPPD disease families (see Table I for compilation of
ANKH mutations in familial CPPD disease).
To evaluate the relevance of mutations in ANKH to
idiopathic CPPD disease, Pendleton et al. studied 95 CPPD
disease patients from the UK. One patient, who presented
with late-onset CPPD deposition in several joints, displayed
a 3 bp in-frame deletion in exon 12 that eliminated
a glutamic acid at amino acid position 490. This change,
like those observed in the familial mutations, was not
observed in any controls. The same change was observed
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disease could not be conﬁrmed in these individuals41.
Recently, Zhang et al.44 sequenced ANKH in a small cohort
of sporadic CPPD patients and performed follow-up studies
of detected sequence variants in a larger cohort of sporadic
CPPD disease patients (nZ 104) and controls (nZ 500).
They detected a signiﬁcant association between sporadic
CPPD disease and a polymorphism in the 5# UTR of ANKH
at position 4 bp with respect to the A of the ATG initiation
of translation codon.
GENETIC HETEROGENEITY IN FAMILIAL CPPD DISEASE
Interestingly, not all families with CPPD disease are
linked to the CCAL1 or CCAL2 loci that have been identiﬁed
by linkage analyses. For example, the multi-generation
family described by Eshel et al.18 failed to exhibit linkage to
either loci when genotyped with markers selected from the
two candidate regions, CCAL1 and CCAL2 (Baldwin C and
Williams CJ, unpublished data). These ﬁndings suggest that
another uncharacterized locus may be responsible for the
familial CPPD disease phenotype in this kindred.
THE FUNCTION OF ANK IN CPPD DISEASE
Studies of ank function in cells from the progressive
ankylosis mouse and in COS cells transfected with normal
and mutant ank suggested that the protein may regulate
transport of PPi. Ho et al.35 showed that intracellular PPi
levels in ﬁbroblasts from mutant mice were increased about
twofold over that of wild type controls, and that extracellular
levels of PPi were dramatically reduced in ﬁbroblast
cultures derived from mutant ank mice compared to wild
type controls. Since PPi is a potent inhibitor of hydroxyap-
atite deposition in cartilage and bone, reduction in
extracellular levels of PPi could account for the excessive
calciﬁcation phenotype seen in ank/ank mice. Further
experiments by Ho et al. showed that ﬁbroblasts from
mutant mice could be restored to normal levels of
intracellular and extracellular PPi when transfected with
wild type ank. They also showed that over-expression of
wild type ank in COS cells resulted in a dramatic decrease
in intracellular PPi levels and a concomitant increase in
extracellular PPi levels. Finally, the decreased levels of
intracellular PPi resulting from over-expression of ank in
COS cells could be restored by the addition of probenecid,
a non-speciﬁc anion transport inhibitor, suggesting that ank
functioned via an ion channel transport mechanism.
In order to evaluate the impact of dominant mutations in
ANKH observed in two families on the function of the ANK
protein, Pendleton et al. transfected COS cells with
constructs containing the INSC 4 and Met48Thr mutants.
Interestingly, the familial mutations did not signiﬁcantly alter
intracellular PPi levels. To explain this result, Pendleton
Table I
ANK mutations in families with CPPD disease
Family Amino acid position Type of mutation Reference
British NA INSC 4* 41
French 48 Met4 Thr 41
Argentinean 5 Pro4 Leu 42
US 5 Pro4 Thr 43
US 5 Pro4 Thr 43
*INSC 4: insertion of four amino acids at the N-terminus of ANK.et al.41 hypothesized that, in contrast to the ank mouse
mutant, the human CPPD disease mutations might act as
gain-of-function alleles which would moderately increase
extracellular PPi levels over time, leading to subtle
abnormalities that have a minor and cumulative impact on
articular cartilage homeostasis.
Recent studies of a familial ANKH mutation (Pro5Leu42)
and two sporadic ANKH mutations (4 bp, 5# UTR44 and
deletion of Glu49041) in an immortalized human chondro-
cyte cell line demonstrated an increase in the transcription
and translation of ANK. Furthermore, transfection of the
4 bp (5# UTR) ANKH variant into the CH-8 cell line
resulted in elevated levels of extracellular PPi. However,
other ANKH mutants, speciﬁcally the Pro5Leu and
Met48Thr, and delGlu490 mutations, had divergent effects
on the elaboration of extracellular PPi in this cell system44.
Our own studies have examined the impact of three familial
missense mutations in ANKH identiﬁed by us (Met48Thr,
Pro5Leu and Pro5Thr) on the elaboration of extracellular
PPi as well as ecto-nucleotide pyrophosphohydrolase and
alkaline phosphatase activity in stably transduced, chon-
drogenic ATDC5 cells. Our results demonstrate statistically
signiﬁcant increases in extracellular PPi in all mutants
examined, thus conﬁrming the gain-of-function hypothe-
sized by Pendleton et al. [Zaka R, Stokes D, Dion AS,
Kusnierz A, Han F, and Williams CJ, manuscript submitted].
Figure 2 illustrates the proposed structure and function
for the ANK protein. Under conditions of homeostasis, ANK
facilitates the transport of PPi, thus ensuring appropriate
levels of extracellular PPi to inhibit calciﬁcation of articular
cartilage. However, in the ank/ank mouse, in which
a recessive mutation in the ank gene produces non-
functional ank protein, there is a decrease in the efﬂux of
PPi from the cell, resulting in the deposition of hydroxyap-
atite in articular cartilage. Finally, in the case of familial
CPPD disease mutations, there is increasing evidence that
the ANKH mutations result in an excess of extracellular PPi
and may promote the deposition of CPPD crystals in
articular cartilage.
Familial hydroxyapatite deposition disease:
phenotype and genetic analyses
There are few reports of the deposition of hydroxyapatite
and other basic calcium phosphate crystals as a heritable
disorder in themedical literature, and theearliest descriptions
were of calciﬁc periarthritis in multiple joints of identical
twins45, and in relatives of a proband presenting with
intervertebral disc calciﬁcation46. In a casewhere the primary
crystal type was determined to be basic calcium phosphate,
the phenotype mainly involved the dorsolumbar spine, with
intervertebral disc calciﬁcation primarily in the nucleus
pulposus, as well as the peripheral joints with periarticular
calciﬁc deposits in the hand joints. This phenotype was
displayedby the family described byMarcoset al. in 198147 in
which no family members displayed calciﬁc deposits in the
knees, pubic symphysis, or triangular ligament of the carpus,
thus distinguishing the hydroxyapatite arthropathy in this
family from the condition seen in patients with familial CPPD
disease.
Caspi et al.48 described three members of another family
in which periarthritis of multiple joints was observed, but
with an exclusive crystal type of octacalcium phosphate, as
conﬁrmed by Fourier transform infrared spectrophotometry
of an open biopsy of a calciﬁcation of a proximal in-
terphalangeal joint. This crystal type often accompanies
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Fig. 2. Putative structure and function of ANK. Panel A: The transmembrane prediction algorithm, TMpred152, suggests that ANK, the 492
amino acid gene product of ANKH, is a multipass transmembrane protein with 10 transmembrane helices. The positions of mutations in
familial CPPD disease, relative to the position of the naturally occurring recessive mutation in the ank/ank mouse (which occurs at amino acid
440, changing a glutamic acid residue to a stop codon) are shown. Symbols: indicates potential N-glycosylation site; potential
phosphorylation sites by protein kinase C or cAMP/cGMP dependent protein kinase. Panel B: Proposed impact of mutations on PPi
generation. ANK appears to act as a channel or transporter for the inorganic anion, PPi. Under normal conditions, there is presumably
a homeostasis in PPi transport such that extracellular PPi inhibits calciﬁcation of articular cartilage. A recessive mutation in the ank/ankmouse
produces a decrease in extracellular PPi35, permitting deposition of hydroxyapatite. Dominant mutations in humans affected with CPPD
disease may lead to excess efﬂux of PPi44 (Zaka et al., manuscript submitted); excessive extracellular PPi may ultimately result in the
deposition of CPPD crystals in articular cartilage.deposits of carbonate substituted hydroxyapatite, but the
ﬁnding of octacalcium phosphate alone in a biopsy spec-
imen is unique to this family. Another unusual observation
in this kindred was the fact that affected individuals
displayed low serum alkaline phosphatase activityda
ﬁnding not seen in other families with basic calcium
phosphate arthropathies. No follow-up genetic studies have
yet been preformed on this kindred.
A detailed description of an erosive arthritis of the
shoulder, known as ‘‘Milwaukee shoulder’’ was published
by McCarty et al.49. In this disorder, apatite crystal de-
position in the shoulder begins with limited joint mobility and
stability, accompanied by joint effusion, and progresses to
degenerative changes to the scapula or humeral head and
the acromioclavicular joint, and calciﬁcation of the rotator
cuff. Rotator cuff tear is common. A family of four members
with calciﬁc periarthritis of the shoulder was described by
Hajiroussou and Webley in 198350 but a more detailed
description of a large Italo-Argentinean kindred with
Milwaukee shoulder was recently reported51. This family
displayed an unusual type of osteoarthritis with secondary
intraarticular and periarticular calciﬁcation in numerous
joints, along with Milwaukee shoulder in the most severely
affected elderly members and evidence of superior shoulder
subluxation in younger members. Examination of synovialﬂuid from the shoulders of two affected family members
showed the presence of both hydroxyapatite and CPPD
crystals. Some genetic studies of this family were performed
and are described below.
GENETIC LINKAGE ANALYSES AND THE STATUS OF
CANDIDATE GENE ANALYSES IN FAMILIES WITH
HYDROXYAPATITE DEPOSITION DISEASE
Because of the rarity of familial hydroxyapatite/basic
calcium phosphate arthropathy, genetic analysis of kindred
afﬂicted with these disorders has been limited. Studies of
the Italo-Argentinean kindred described above indicated
that the disorder was inherited in an autosomal dominant
manner. While the phenotype in the family was not
consistent enough to warrant a genome-wide search for
linkage to a putative disease-causing locus, it was sufﬁcient
for analysis of potential candidate loci. The loci that were
targeted included the chondrocalcinosis loci on chromo-
somes 8q and 5p15, and the COL2A1 locus on chromosome
12q. These loci were deﬁnitively excluded in the family.
Several other loci that have been implicated in normal
skeletal patterning and cartilage differentiation, the HOX A,
B, C, and D gene cluster and the PAX 1 and 9 genes, were
also analyzed. These loci were either excluded or were
749Osteoarthritis and Cartilage Vol. 13, No. 9uninformative in terms of their linkage to the disease
phenotype of Milwaukee shoulder/subluxation in the kin-
dred51.
Finally, observations of mineralization defects in the ank
mutant mouse indicated that hydroxyapatite deposition was
the crystal type deposited in articular spaces. Therefore,
two other families displaying autosomal dominant hydroxy-
apatite deposition disease that have not been reported in
the literature but have been studied by us were screened for
mutations in ANKH. No sequence variants in the coding
regions of the ANKH gene were observed in these families
(Kingsley D and Williams CJ, unpublished observations).
Conclusions
This review has attempted to recapitulate the develop-
ment of the genetic studies of the inherited non-urate crystal
arthropathies. The progress in our understanding of these
disorders is in large part due to the identiﬁcation of families
in which the calcium crystal-associated arthropathies are
inherited in a Mendelian manner, thus permitting the use of
traditional methods of parametric linkage analysis to
establish loci that are linked to the phenotype in these
families. Also, the availability of high-throughput techniques
for genotype analyses and candidate gene analysis has
signiﬁcantly increased the speed with which suitable
kindreds can be analyzed. Furthermore, animal models
presenting with skeletal abnormalities associated with
pathological mineralization have proven to be an out-
standing resource for providing suggestions of potential
candidate genes that may warrant analysis in families
suffering from crystal arthopathies. At this time, there is
every reason to believe that population-based studies of
susceptibility genes for the crystal arthropathies will,
likewise, contribute to our understanding of the complexity
of inheritance of these disorders. Clearly, close cooperation
between clinical and basic science researchers will hasten
the identiﬁcation of genetic loci whose gene products
contribute to those biochemical pathways that are re-
sponsible for the pathology of the non-urate crystal
disorders.
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